Cited by 47Academic Publishing and Open AccessPharmaceutical industry and healthcareResearch Data Management Practices

Biotech giant publishes failures to confirm high-profile science

Open access
Baker, Monya·2016·Nature

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature.2016.19269

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Bayer Healthcare reported that they were only able to verify 25% of preclinical research.

    “Bayer Healthcare released a similar report disclosing that they were only able to verify 25% of preclinical research [38,39].”

    From The history, landscape, and outlook of human cell line authentication and security (2024) · cites this paper as [38]

    The IRREPRODUCIBLE HISTORY section reports that Amgen could not reproduce findings in 47 of 53 cancer papers; it does not report a Bayer Healthcare result. Searches for Bayer, 25%, and a quarter of preclinical findings found no passage addressing the claimed figure. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Baker, M.
Corresponding author
Baker, Monya
Venue
Nature
Published
2016-02-04
Volume
530
Issue
7589
Pages
141-141
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2259670296
Cited by
47
References
2
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 6 · 2019: 7 · 2018: 6 · 2017: 2 · 2016: 8
Type
other
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Social Sciences › Decision Sciences › Information Systems and Management › Academic Publishing and Open Access
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
  • Physical Sciences › Computer Science › Information Systems › Research Data Management Practices
Keywords
Amgen, reproducibility, replication failure, research integrity, scholarly publishing, online forums, pharmaceutical industry research
MeSH terms
Biotechnology, Drug Industry, United States, Reproducibility of Results, Uncertainty, Biomedical Research, Open Access Publishing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review